Clene (CLNN)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) t...
- Open
- 4.670
- High
- 4.802
- Low
- 4.400
- Prev. Close
- 4.650
- Volume
- 13.61K
- Turnover
- 61.76K
- Avg Price
- 4.538
- Bid/Ask Ratio
- -85.19%
- Amplitude
- 8.65%
- 52wk High
- 13.500
- Volume Ratio
- 0.67
- Turnover Ratio
- 0.15%
Clene Analyst Rating
View moreForecast & Rating
Aug 18, 2026Price forecast
$32.20618.75%
Forecast & RatingStrong buy
5analysts
- Strong buy80.00%
- Buy20.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Aug 19 at 05:03 PM
Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses
- PUBT · Aug 17 at 07:30 AM
Clene to Present Corporate Update at Emerging Growth Conference
- Earnings Watch · Aug 14 at 07:48 AM
Clene | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 90 K
- Unusual Whales · Aug 14 at 07:32 AM
Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
- PUBT · Aug 14 at 07:04 AM
Clene Q2 FY26 net loss widens 81% to $13.42 million
- Market Beat · Aug 12 at 05:02 AM
Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS
